Research project designed to investigate the use of an automated insulin delivery system in combination with a dose of empagliflozin (SGLT2 inhibitor) in people living with type 1 diabetes with suboptimal glycemic time in range. (EMPA-6 months)
Implication
The Montreal Clinical Research Institute (IRCM) is seeking participants for a research project under the supervision of Dr. Rémi Rabasa-Lhoret (IRCM).
This 6-month intervention study involves 3 or 4 face-to-face visits.
- The primary objective is to verify the safety and efficacity of empagliflozin(2.5mg daily) in combination with an automated insulin delivery system (artificial pancreas) in people with a time in glycemic target (3.9-10 mmol/L) of less than 70%
- If you are eligible, you will be assigned to treatment or placebo for 6 months.
- You will continue to use your own artificial pancreas system.
- Visits will involve blood tests, questionnaires and questions about your state of health.
- You'll have the opportunity to update your knowledge of type 1 diabetes management and optimize your treatment.
- Financial compensation will be offered for your participation.
During the study period, you will continue using your own diabetes treatment.
Inclusion criteria
- Have lived with type 1 diabetes for at least 1 year
- Be over 18 years old
- Have used an automated insulin delivery system for (AID) more than 3 months
- Be physically active, exercising at least twice-weekly
- Having a time in range of less than 70% in the 30 days prior to inclusion
Informations
Valérie Boudreau, coordonnatrice de recherche
Téléphone: 514-987-5643
valerie.boudreau@ircm.qc.ca
